R

Arcus Biosciences
D

RCUS

14.570
USD
-0.13
(-0.88%)
Market Closed
Volume
9,429
EPS
-3
Div Yield
-
P/E
-5
Market Cap
1,333,324,143
OverviewSignalsIdeasNews
Related Instruments
    A
    ARWR
    -2.890
    (-13.49%)
    18.540 USD
    C
    CRIS
    -0.04000
    (-1.00%)
    3.96000 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    K
    KPTI
    -0.02960
    (-3.54%)
    0.80740 USD
    M
    MGTA
    0
    (0%)
    0.000000 USD
    R
    RCKT
    -0.810
    (-5.48%)
    13.980 USD
    More
News

Title: Arcus Biosciences

Sector: Healthcare
Industry: Biotechnology
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.